A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Basic science
Enrollment
18actual
Sites
2
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-03 | actual | When the study began enrolling |
| Primary completion | 2025-12-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Adults
Interventions
- Drug: PF-08049820
- Drug: Rabeprazole — also filed as Pariet
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of PF-08049820.
measured Day 1 through Day 38-45
PK: Area under the plasma concentration (AUC) of PF-08049820
measured Day 1 through Day 38-45
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed